Prokidney announces two abstracts selected for presentation at the american society of nephrology's kidney week 2025

Winston-salem, n.c., oct. 20, 2025 (globe newswire) -- prokidney corp. (nasdaq: prok) (“prokidney” or the “company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (ckd), today announced that the company will present two posters, including a late-breaking poster on the phase 2 regen-007 study results, at the upcoming american society of nephrology's (asn) kidney week being held from november 6-9, 2025, in houston, tx.
PROK Ratings Summary
PROK Quant Ranking